Cue Biopharma, Inc. Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
Cue Biopharma, Inc. (CUE) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of -$10.96 thousand for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-14.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2019-03-14
- Cue Biopharma, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2018-12-31 was $9.04K.
- Cue Biopharma, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2018-09-30 was -$20.00K.
- Cue Biopharma, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2018 was -$10.96K.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2018-12-31 | $9.04K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14 | -$10.96K derived: sum of 2 quarters · filed 2019-03-14 | -$10.96K 10-K · filed 2019-03-14 | |
| 2018-09-30 | -$20.00K 10-Q · filed 2018-11-13 | -$20.00K 10-Q · filed 2018-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |